Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

William G. Wierda, Nirav N. Shah, Chan Y. Cheah, David Lewis, Marc Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna Rhodes, Matthew McKinney, Ewa Lech‐Marańda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Philip A. Thompson, Paolo Abada, Caleb Ho, Samuel McNeely, Narasimha Marella, Bastien Nguyen, Chunxiao Wang, Amy S. Ruppert, Binoj C. Nair, Hui Liu, Donald E. Tsai, Lindsey E. Roeker, Paolo Ghia